Acadia Pharmaceuticals announced the appointment of Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the Company’s Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia.
“Tina brings a wealth of experience in global business development and strategic partnerships that will be instrumental as we continue to expand our pipeline and pursue high-impact growth opportunities,” said Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals. “Her leadership and deep industry knowledge will be invaluable as we advance our mission to improve the lives of patients affected by neurological and rare disease.”
Health Technology Insights: Merz Begins Phase III Trials of XEOMIN for Migraine Prevention
Ms. Katcheves brings over two decades of experience in the biopharmaceutical industry spanning corporate strategy, M&A, and innovation leadership. Most recently, she served as Senior Vice President, Global Business Development at Teva Pharmaceuticals, where she oversaw the expansion of Teva’s innovative medicines pipeline and built new internal and external capabilities to support long-term portfolio advancement. Prior to Teva, she held multiple senior executive roles at Bristol Myers Squibb (BMS), including Interim Head of Enterprise Strategy and Business Development. At BMS, she led the $14 billion acquisition of Karuna Therapeutics and drove more than $18 billion in announced transactions, supporting both near-term revenue growth and long-term pipeline innovation. Prior to BMS, she held senior strategic roles at Agilent Technologies and Lonza Group.
Health Technology Insights: Stacy Giles Named COO of Greater Boston Urology
“I’m thrilled to join Acadia as it enters a new phase of innovation and expansion,” said Tina Katcheves. “I look forward to working with the talented team at Acadia to identify and execute strategic initiatives that will drive innovation and deliver meaningful therapies to patients.”
Tina holds a Master of Science in Biotechnology from Johns Hopkins University, a Juris Doctor from the University of Oklahoma School of Law, and a Bachelor of Science in Biochemistry and Cell Biology from the University of California, San Diego.
Health Technology Insights: Vizient Procure-to-Pay Achieves ISO 9001 Certification
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- businesswire
